Innate sees no development path for lirilumab combo therapies

Innate Pharma S.A. (Euronext:IPH) said efficacy data from a Phase I/II trial of lirilumab (BMS-986015, IPH2102) in combination with Opdivo nivolumab to treat head and neck cancers

Read the full 274 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE